PFE vs V: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-19.
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
VS
Visa Inc. · Financial Services
$368.29
+25.7% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
V has more upside to fair value
(+25.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
V |
| Current Price |
$27.64 |
$368.29 |
| Fair Value Estimate |
$30.94 |
$463.00 |
| Upside to Fair Value |
+12.0%
|
+25.7%
|
| Market Cap |
$157.5B |
$687.6B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.4x
|
24.0x
|
| Price / Sales |
2.5x
|
15.5x
|
| Price / FCF |
14.3x
|
33.5x
|
| Revenue Growth YoY |
+2.6%
|
+14.4%
|
| Gross Margin |
71.3%
|
80.2%
|
| Operating Margin |
25.1%
|
60.7%
|
| Return on Equity |
4.9%
|
61.3%
|
| Dividend Yield |
6.22% |
0.73% |
| FCF Yield |
6.97%
|
2.98%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Visa operates the world's largest retail payments network, connecting consumers, merchants, issuers, and acquirers through VisaNet, which authorizes, clears, and settles transactions across more than 200 countries. The business quality is exceptional: TTM gross margin of 80.2%, operating margin of 60.7%, net margin of 50.8%, and ROE of 61.3% reflect a two-sided network with powerful scale economi…
Accumulation Zones
| Metric |
PFE |
V |
| Zone Low |
$23.21 |
$347.25 |
| Zone High |
$26.30 |
$393.55 |
| In Buy Zone? |
No
|
Yes
|